St Jude Medical buys up Epicor stocks
This article was originally published in Clinica
St Jude Medical has acquired Epicor Medical in a $185m cash transaction, having previously made a $15m investment in the developer of an epicardial ablation system for treatment of atrial fibrillation (AF). St Jude had taken a minority stake in Epicor in May 2003 (see Clinica No 1056, p 17) and under the agreement, it reserved the right to buy the Sunnyvale, California-based company outright in 2004 providing certain clinical and regulatory milestones were met.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.